Page 174 - Genentech News Today

A first-line lymphoma treatment shown to reduce the risk of disease progression or relapse by 27 percent has been approved by the FDA.

The global Cytokine Release Syndrome Management Market is expected to reach US$ 23.32 billion in 2023, with a 6.7% CAGR from 2023 to 2033. In the coming years, the market for CRS management is expected to grow due to an increase in the number of autoimmune diseases and cancers.The development of novel therapies for...

The CEO Roundtable on Cancer was among several organizations represented at the meeting convened by the National Minority Quality Forum.

The obituary for Leslie Jay Schroeder, who worked for Pacific Bell for many years before taking a number of other interesting jobs, including a stint in Berlin for Fujitsu. He was also an avid cyclist.

The obituary for Leslie Jay Schroeder, who worked for Pacific Bell for many years before taking a number of other interesting jobs, including a stint in Berlin for Fujitsu. He was also an avid cyclist.

VB10.16 Final Phase 2 data readout - 12 month treatment follow up April 19 2023 ... | April 19, 2023

Pembrolizumab led to a dramatic overall response rate among patients with unresectable desmoplastic melanoma.

Victor Davis Hanson on the pestilence in northern California.

Patients were randomly assigned to receive atezo + bev for a period of one year or 17 cycles or to undergo active surveillance.

Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin lymphoma